Celsion's Phase III trial of ThermoDox to continue
This article was originally published in Clinica
Executive Summary
Celsion's trial of its ThermoDox heat-activated therapy for cancer will continue on track, having passed a Data Monitoring Committee (DMC) assessment which will enable the company to keep enrolling patients. However, the global Phase III HEAT study, a pivotal trial of ThermoDox in combination with radiofrequency ablation (RFA) for primary liver cancer, may not yet resume enrollment of patients in Japan.